A pharmaceutical company, “HealthInnovate Inc.,” has developed a promising experimental drug intended to treat a rare and severe medical condition. The drug has shown remarkable results in early clinical trials, and the company is seeking approval from regulatory authorities to bring it to market. However, the drug is not yet approved for general use, and its availability is currently limited to a small number of patients who meet specific criteria. A growing number of patients and advocacy groups are calling for expanded access to the drug, arguing that its potential benefits outweigh the risks of using an unapproved treatment. The situation has become increasingly complex as media coverage highlights stories of patients who are suffering from the condition and believe that the experimental drug could significantly improve their quality of life. Some patients have petitioned for compassionate use or expanded access to the drug outside of clinical trials. HealthInnovate Inc. is facing ethical dilemmas regarding how to handle these requests. On one hand, the company wants to ensure that the drug is safe and effective before widespread use. On the other hand, there is a strong moral argument for providing access to patients who are in desperate need of treatment. (a) Discuss the ethical principles involved. (b) What criteria should be established to determine which patients receive access to experimental treatments. How can these criteria be applied ethically to avoid favoritism or discrimination?

Answered by 2 toppers · CSE 2024

Syllabus: Case Studies on above issues.